+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Meningococcal disease risk for international travellers and vaccine strategies



Meningococcal disease risk for international travellers and vaccine strategies



Travel Medicine And Infectious Disease: 4, 182-186



International travel and migration facilitate the rapid intercontinental spread of meningococcal disease. Serogroup A and, less so serogroup C, have been responsible for epidemics in the past (mainly in Africa). In recent years, W135 has emerged (first in Saudi Arabia, then in West Africa) as a serogroup that requires attention. Serogroups X and Y are infrequent, but associated with slowly rising trends.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 032299544

Download citation: RISBibTeXText


Related references

Meningococcal disease: risk for international travellers and vaccine strategies. Travel Medicine and Infectious Disease 6(4): 182-186, 2008

Meningococcal disease: Vaccine strategies for travelersThe risk of dengue to international travellers. Travel Medicine and Infectious Disease 5(6): 401-402, 2007

Meningococcal disease in international travel: vaccine strategies. Journal of Travel Medicine 12(Suppl. 1): S22-S29, 2005

Vaccine prevention of meningococcal disease in adolescents and travellers. International Health 2(4): 229-230, 2010

Risk of invasive meningococcal disease in university students in England and optimal strategies for protection using MenACWY vaccine. Vaccine 35(43): 5814-5818, 2017

Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine and a quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135, and Y in adults who are at increased risk for occupational exposure to meningococcal isolates. Clinical and Vaccine Immunology 18(3): 483-486, 2011

A comparison of exposure to risk factors for giardiasis in non-travellers, domestic travellers and international travellers in a Canadian community, 2006-2012. Epidemiology and Infection 144(5): 980-999, 2016

High Risk for Invasive Meningococcal Disease Among Patients Receiving Eculizumab (Soliris) Despite Receipt of Meningococcal Vaccine. Mmwr. Morbidity and Mortality Weekly Report 66(27): 734-737, 2017

Recommendation of the Advisory Committee on Immunization Practices (ACIP) for use of quadrivalent meningococcal conjugate vaccine (MenACWY-D) among children aged 9 through 23 months at increased risk for invasive meningococcal disease. Mmwr. Morbidity and Mortality Weekly Report 60(40): 1391-1392, 2011

Recommendation from the advisory committee on immunization practices (ACIP) for use of quadrivalent meningococcal conjugate vaccine (MCV4) in children aged 2-10 years at increased risk for invasive meningococcal disease. 2007

Reduction of travellers' diarrhoea by WC/rBS oral cholera vaccine in young, high-risk travellers. Vaccine 27(30): 4074-4077, 2009

Licensure of a meningococcal conjugate vaccine for children aged 2 through 10 years and updated booster dose guidance for adolescents and other persons at increased risk for meningococcal disease--Advisory Committee on Immunization Practices (ACIP), 2011. Mmwr. Morbidity and Mortality Weekly Report 60(30): 1018-1019, 2011

Meningococcal vaccination for international travellers from Greece visiting developing countries. Travel Medicine and Infectious Disease 14(3): 261-266, 2017

Vaccine strategies of meningococcal disease: results of a 10-year population-based study. European Journal of Pediatrics 164(12): 735-740, 2005

The use of the Internet to inform young international travellers of contact with a case of meningococcal meningitis. Canada Communicable Disease Report 28(5): 37-40, 2002